Pharma Q3 Preview - Margins To Remain Under Pressure; Domestic Market Growth To Slow Down: Nirmal Bang
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Nirmal Bang Report
While we had seen some Indian pharmaceutical companies face margin pressure in Q2 FY22, we do not expect any relief in Q3 FY22 either. Margins should be affected by higher active pharma ingredient prices, rise in vial costs (for injectables) and increase in freight costs.
We expect sales of Covid-19 driven products in the domestic branded formulation segment to dissipate on a YoY basis, as new Covid-19 cases declined in Q3 FY22.
U.S. volume growth remains flattish, with a few exceptions in specific companies – Biocon Ltd. and Sun Pharmaceutical Industries Ltd. We expect growth in small molecule sales of Biocon on account of limited-competition launch of Everolimus 10mg. Sun Pharma should gain on the back of ramp-up in Winlevi, Sutent and Levulan.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.